论文部分内容阅读
目的:研究DNA切除修复交叉互补基因1(excision repair cross-complementing gene1,ERCC1)单核苷酸多态性与非小细胞肺癌铂类药物化疗敏感性的关系。方法:应用基因测序方法检测89例以铂类药物为主要化疗方案的非小细胞肺癌患者的ERCC1 Asn118Asn基因型,,比较不同基因型与化疗疗效的关系。结果:89例患者化疗总有效率为29.2%。携带ERCC1 CC基因型、含至少一个变异基因型(TC和TT基因型)患者的有效率分别为38.5%和61.5%(X2=2.151,p=0.142),基因型在化疗有效组和无效组之间的分布无差异(p>0.05)。结论:ERCC1Asn118Asn单核苷酸多态性可能与非小细胞肺癌对铂类药物化疗的敏感性无关。
OBJECTIVE: To study the relationship between DNA excision repair cross-complementing gene 1 (ERCC1) single nucleotide polymorphism and chemosensitivity of non-small cell lung cancer (NSCLC) platinum drugs. Methods: The genotype of ERCC1 Asn118Asn in 89 patients with non-small cell lung cancer who were treated with platinum-based chemotherapy was detected by gene sequencing method. The relationship between different genotypes and chemotherapy efficacy was compared. Results: The total effective rate of chemotherapy in 89 patients was 29.2%. The patients with ERCC1 CC genotype and at least one mutation genotype (TC and TT genotypes) were 38.5% and 61.5%, respectively (X2 = 2.151, p = 0.142). The genotypes were significantly higher in the chemotherapy- No difference between the distribution (p> 0.05). Conclusion: The single nucleotide polymorphism of ERCC1Asn118Asn may not be related to the sensitivity of non-small cell lung cancer to platinum-based chemotherapy.